Delivering nanomedicines to patients: A practical guide

Eaton, Mike; Lévy, Laurent; Fontaine, Olivier

doi:10.1016/j.nano.2015.02.004

Cited by 65 publications

(46 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly to other pharmaceuticals, the clinical potential of the nanocarrier is evaluated based on a risk-benefit ratio analysis. 93 Nonetheless, our flow cytometry data suggested that if PEG-AuNPs were to be used in vivo as nanocarriers, no severe cytotoxicity should be elicited by either the nanomaterial itself or its organic PEG coating in the pancreas. This resulted to be in line with the nanocarrier safe-by-design approach 16 adopted.…”

Section: Discussionmentioning

confidence: 77%

Targeted polyethylene glycol gold nanoparticles for the treatment of pancreatic cancer: from synthesis to proof-of-concept in vitro studies

Spadavecchia¹,

Movia²,

Moore³

et al. 2016

IJN

167

View full text Add to dashboard Cite

International audienceThe main objective of this study was to optimize and characterize a drug delivery carrier for doxorubicin, intended to be intravenously administered, capable of improving the therapeutic index of the chemotherapeutic agent itself, and aimed at the treatment of pancreatic cancer. In light of this goal, we report a robust one-step method for the synthesis of dicarboxylic acid-terminated polyethylene glycol (PEG)-gold nanoparticles (AuNPs) and doxorubicin-loaded PEG-AuNPs, and their further antibody targeting (anti-Kv11.1 polyclonal antibody [pAb]). In in vitro proof-of-concept studies, we evaluated the influence of the nanocarrier and of the active targeting functionality on the anti-tumor efficacy of doxorubicin, with respect to its half-maximal effective concentration (EC50) and drug-triggered changes in the cell cycle. Our results demonstrated that the therapeutic efficacy of doxorubicin was positively influenced not only by the active targeting exploited through anti-Kv11.1-pAb but also by the drug coupling with a nanometer-sized delivery system, which indeed resulted in a 30-fold decrease of doxorubicin EC50, cell cycle blockage, and drug localization in the cell nuclei. The cell internalization pathway was strongly influenced by the active targeting of the Kv11.1 subunit of the human Ether-à-go-go related gene 1 (hERG1) channel aberrantly expressed on the membrane of pancreatic cancer cells. Targeted PEG-AuNPs were translocated into the lysosomes and were associated to an increased lysosomal function in PANC-1 cells. Additionally, doxorubicin release into an aqueous environment was almost negligible after 7 days, suggesting that drug release from PEG-AuNPs was triggered by enzymatic activity. Although preliminary, data gathered from this study have considerable potential in the application of safe-by-design nano-enabled drug-delivery systems (ie, nanomedicines) for the treatment of pancreatic cancer, a disease with a poor prognosis and one of the main current burdens of today’s health care bill of industrialized countries

show abstract

Section: Discussionmentioning

confidence: 77%

Targeted polyethylene glycol gold nanoparticles for the treatment of pancreatic cancer: from synthesis to proof-of-concept in vitro studies

Spadavecchia¹,

Movia²,

Moore³

et al. 2016

IJN

167

View full text Add to dashboard Cite

show abstract

“…In order for this to happen, what is now needed, more than anything else, is effective and co-ordinated leadership to lead the commercial charge for dendrimer drugs as marketable medicines. In 2015, this has also been highlighted by other investigators in the field [74].…”

Section: My Perspective On Dendrimer Drugs As Medicines To Marketmentioning

confidence: 67%

Perspective: Dendrimer drugs for infection and inflammation

Shaunak

2015

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

“…[2] Indeed, leaving residues of therapeutics in patients is not acceptable, as one of the key-question of regulatory agencies is related to the excretion rate of nanomaterials after the designed action. [5] Noble metal nanoparticles (NPs) are not biodegradable, resulting in their long-term persistence within excretion system organs, such as liver. [6] On the other hand, NPs are of increasing interest for the advancement of cancer treatments, as demonstrated in many animal models, due to their intrinsic multi-functionalities related to high electron density and peculiar interaction with electromagnetic waves.…”

Section: Doi: 101002/ppsc201800464mentioning

confidence: 99%

“…To date, there are still no approved noble metal nanomaterials for cancer therapy . Indeed, leaving residues of therapeutics in patients is not acceptable, as one of the key‐question of regulatory agencies is related to the excretion rate of nanomaterials after the designed action . Noble metal nanoparticles (NPs) are not biodegradable, resulting in their long‐term persistence within excretion system organs, such as liver .…”

Section: Introductionmentioning

confidence: 99%

Biodegradable Ultrasmall‐in‐Nano Gold Architectures: Mid‐Period In Vivo Distribution and Excretion Assessment

Cassano

Summa

Pocoví‐Martínez

et al. 2018

Part & Part Syst Charact

View full text Add to dashboard Cite

The persistence of metals in the body after the designed theranostic action has hampered the clinical translation of noble metal nanoparticles (NPs) to clinics. Therefore, the appealing behaviors of NPs for healthcare applications are still on the bench‐side. Here, quantitative evaluation in healthy murine models show that gold comprised in passion fruit‐like nanoarchitectures (NAs) are excreted daily over a 10 d period by both renal and biliary pathways after biodegradation to the building blocks. Furthermore, histological analyses confirm the absence of nephrotoxicity and the remarkable biocompatibility of NAs up to the higher tested amount of 150 mg kg−1. These in vivo findings demonstrate that NAs are the first full‐inorganic disassembling nanoplatforms exhibiting a noticeable excretion rate from model organisms. Such results are a significant step in bringing noble metal nanotheranostics to the forefront of cancer treatments once again.

show abstract

Delivering nanomedicines to patients: A practical guide

Cited by 65 publications

References 8 publications

Targeted polyethylene glycol gold nanoparticles for the treatment of pancreatic cancer: from synthesis to proof-of-concept in vitro studies

Targeted polyethylene glycol gold nanoparticles for the treatment of pancreatic cancer: from synthesis to proof-of-concept in vitro studies

Perspective: Dendrimer drugs for infection and inflammation

Biodegradable Ultrasmall‐in‐Nano Gold Architectures: Mid‐Period In Vivo Distribution and Excretion Assessment

Contact Info

Product

Resources

About